EP. 1: Role of Genetics & Pathogenesis of Plaque PsoriasisNovember 20th 2020
As an introduction to a panel discussion on best practices using newer, novel therapies to treat plaque psoriasis, dermatology experts review what is now understood regarding the condition’s pathophysiology.
EP. 2: Plaque Psoriasis: Clinical Presentation & Impact on PatientsNovember 20th 2020
April W. Armstrong, MD, MPH, of the University of Southern California, comments on the clinical manifestation of plaque psoriasis on children and adult patients, and highlights comorbidities typically associated with the condition.
EP. 5: Biologic Therapies for Plaque Psoriasis: SafetyNovember 20th 2020
Dermatology experts comment on the safety profiles of biologic therapies used to treat plaque psoriasis, highlight specific contraindications to be mindful of when prescribing these drugs, and provide suggestions to help mitigate the risk of adverse events.
EP. 6: IL-23 Inhibitors for Plaque Psoriasis TreatmentNovember 20th 2020
Andrew Blauvelt, MD, MBA, of Oregon Medical Research Center, highlights a newer class of biologics used to treat plaque psoriasis, IL-23 inhibitors, and explains how they differ from other classes of therapy.
EP. 8: Biologic Treatment for Plaque Psoriasis: Switching TherapyNovember 20th 2020
Recommendations for treating plaque psoriasis with newer biologic therapies and factors that warrant a switch in therapy, either using another biologic of the same class or moving to a different class.
EP. 9: Biologic Therapies for Plaque Psoriasis: Treatment LimitationsNovember 20th 2020
During a brief discussion on current treatment challenges in plaque psoriasis, key opinion leaders in dermatology highlight patient access and affordability of newer biologic therapies as the biggest hurdles faced by clinicians.
EP. 11: Managing Plaque Psoriasis: Expert AdviceNovember 20th 2020
Takeaways from a panel discussion on newer biologic therapies to treat plaque psoriasis, and parting advice to other professionals who work in dermatology regarding best practices when using these drugs in their clinics.